Please login to the form below

Not currently logged in
Email:
Password:

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

CMS proposes coverage scheme for CAR-T therapies

CMS proposes coverage scheme for CAR-T therapies

for CAR T-cell therapy for cases in which the benefits outweigh the risks,” said CMS Administrator Seema Verma. ... The first CAR-T to be approved by the FDA was Novartis’ Kymriah (tisagenlecleucel) for B-cell precursor acute lymphoblastic leukaemia

Latest news

  • CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

    Novartis agrees pricing deal with NHS England. NICE has today approved Novartis’ CAR-T therapy Kymriah for adults with diffuse large B-cell lymphoma (DLBCL), an aggressive form of blood cancer. ... Meindert Boysen, director of the Centre for Health

  • European biosimilars hit AbbVie’s Humira revenues in Q4 European biosimilars hit AbbVie’s Humira revenues in Q4

    in patients with treatment-naïve diffuse large B-cell lymphoma. ... The fate of its Rovalpituzumab Tesirine (Rova-T) also hangs in the balance after it failed in a phase 3 trial for small cell lung cancer in December.

  • Novartis buys CellforCure to bolster cell, gene therapy Novartis buys CellforCure to bolster cell, gene therapy

    m. plant in Les Ulis next year. Kymriah was approved by the EMA in August to treat people aged under 25 with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL) ... and adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

  • CAR-Ts take centre stage as ASH18 comes to a close CAR-Ts take centre stage as ASH18 comes to a close

    Gilead also had new, two-year data to share on its already-marketed CAR-T Yescarta (axicabtagene ciloleucel) in r/r B-cell lymphoma that showed a sustained treatment effect, answering ... Similarly, CAR-T pioneer Novartis reported longer-term data on

  • Gilead strikes deal with NHS England on CAR-T Yescarta Gilead strikes deal with NHS England on CAR-T Yescarta

    Today’s agreement will see around 200 adult patients with diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma be eligible for treatment. ... CAR-T cell therapy is one of the most promising new treatments in a generation for

More from news
Approximately 1 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).  According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's

  • Pharma deals in April 2015 Pharma deals in April 2015

    MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Pharma deals during June 2014 Pharma deals during June 2014

    a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT: Technology transfer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics